R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 58.41 CNY -2.81% Market Closed
Market Cap: 5.6B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Accounts Payable
ÂĄ40.9m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Accounts Payable
ÂĄ2B
CAGR 3-Years
15%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Accounts Payable
ÂĄ503m
CAGR 3-Years
23%
CAGR 5-Years
33%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Accounts Payable
ÂĄ3.1B
CAGR 3-Years
79%
CAGR 5-Years
65%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Accounts Payable
ÂĄ227.1m
CAGR 3-Years
22%
CAGR 5-Years
46%
CAGR 10-Years
31%
W
WuXi XDC Cayman Inc
HKEX:2268
Accounts Payable
ÂĄ620.5m
CAGR 3-Years
417%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
5.6B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
57.24 CNY
Overvaluation 2%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Accounts Payable?
Accounts Payable
40.9m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Accounts Payable amounts to 40.9m CNY.

What is R&G PharmaStudies Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
24%

Over the last year, the Accounts Payable growth was 27%. The average annual Accounts Payable growth rates for R&G PharmaStudies Co Ltd have been 24% over the past three years .

Back to Top